Gradalis, Inc.
16
0
1
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
25.0%
4 terminated/withdrawn out of 16 trials
71.4%
-15.1% vs industry average
6%
1 trials in Phase 3/4
80%
8 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
A Trial of Vigil for Participants With Ovarian Cancer
Role: lead
A Trial of FANG™ Vaccine for Participants With Ovarian Cancer
Role: lead
Expanded Access of Vigil in Solid Tumors
Role: lead
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
Role: lead
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
Role: lead
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Role: lead
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Role: lead
Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Role: lead
Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases
Role: lead
Salvage Ovarian FANG™ Vaccine + Bevacizumab
Role: lead
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
Role: collaborator
Salvage Ovarian FANG™ Vaccine + Carboplatinum
Role: lead
Phase II FANG™ in Advanced Melanoma
Role: lead
Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer
Role: lead
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
Role: lead
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
Role: lead
All 16 trials loaded